Calcium Aluminosilicate clinical trials
A product of Aluminosilicate; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses Calcium Aluminosilicate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
M.D. Anderson Cancer Center (2) · Salient Pharmaceuticals Incorporated (2)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Aluminosilicate
Studies
Open first, then newest update. How each study uses Calcium Aluminosilicate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving IrinotecanCompletedPhase 2M.D. Anderson Cancer CenterNCT00748215Written as calcium aluminosilicate anti-diarrheal
- CASAD for Severe Diarrhea in the Emergency DepartmentTerminatedNot applicableM.D. Anderson Cancer CenterNCT02018653Written as Calcium Alumina-Silicate (CASAD)
- Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile InfectionTerminatedPhase 2Salient Pharmaceuticals IncorporatedNCT01570634Written as Calcium Aluminosilicate Anti-Diarrheal (CASAD)
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid CancerStatus unknownPhase 1/2Salient Pharmaceuticals IncorporatedNCT01739634Written as CASAD
Codes
What other systems call Calcium Aluminosilicate · ClinicalTrials.gg INT006676
- MeSH (NLM) D000077250Calcium AluminosilicateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3L00JH8411CALCIUM ALUMINOSILICATEOne source NLM
- RxNorm 1313228One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077250 | Calcium Aluminosilicate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3L00JH8411 | CALCIUM ALUMINOSILICATE | One source NLM |
| RxNorm | 1313228 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.